“Our work focuses on better understanding the inter- and intra-patient heterogeneity of HGSOC. As the most common subtype of ovarian cancer, HGSOC remains a major clinical challenge worldwide, with advanced-stage disease still associated with poor survival,” they said.

“Using patient samples generously donated by women undergoing surgery at our hospital, we develop clinically relevant models that capture the complexity of this disease and provide unique insights into the tumour microenvironment. Through this work, we aim to uncover new aspects of HGSOC biology, better understand therapy resistance, and develop predictive models to guide more effective and personalised treatments for patients one day.”